U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer's ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was trading at $64.49 ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $ ...

While the momentum for Lilly is accelerating, that for Novo is slowing. In 2024, Lilly and Novo grew by 32% and 26%, respectively. This year, the gulf between their growth is expected to widen ...

Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 700 from DKK 900 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for real ...

BNP Paribas Exane initiated coverage of Novo Nordisk with a recommendation of underperform and a Street-low price target of DKK405.00. The broker cites the obesity drugmaker’s valuation ...

Unfortunately, what's good news for Eli Lilly is probably bad news for investors in Novo Nordisk and Viking Therapeutics, both of which lag Lilly in the race to develop their own easy-to-take GLP ...

Novo Nordisk Warns Consumers About Counterfeit Versions of Ozempic in US (Reuters) - Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic ...

In a report released today, Emily Field from Barclays maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK700.00. Discover outperforming stocks and invest ...